Manager Of Hot New Biotech ETFs Explains The Strategy - Investors.com
This is an outstanding article on BBP, a new biotech ETF that has a double-digit gain since December 2014 along with beating IBB, a stalwart longstanding biotech ETF fund. BBP only invests in drug companies with actual products available, and it has equal weighting no matter what size the companies are. The strategy is working so far.
BBP owns well known companies like Gilead (GILD) as well as lesser known biotechs like Anacor (ANAC), which has outperformed many drug companies this year. I am buying BBP Monday morning while the stock market has pulled back because BBP will be a great ETF to hold long term. People will always need drugs, and BBP is doing great at picking worthwhile biotech companies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment